Afya Limited Unaudited interim condensed consolidated financial statements March 31, 2024 Afya Limited Unaudited interim condensed consolidated statements of financial position As of March 31, 2024 and December 31, 2023 | | Notes | March 31, 2024 | December 31, 2023 | | --- | --- | --- | --- | | | | (unaudited) | | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | 4 | 611,077 | 553,030 | | Trade receivables | 5 | 536,175 | 546,438 | | Inventories | | 653 | 1,382 | | Recoverable taxes | ...

Investors looking for stocks in the Schools sector might want to consider either Afya (AFYA) or Grand Canyon Education (LOPE) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, whi ...

Solskin/DigitalVision via Getty Images Note: This is a Brazilian company. Other than the stock price and valuation where the currency used is in USD, Brazilian Real (BRL) was used. Introduction I covered AFYA (NASDAQ:AFYA) 10 months ago in this article, Afya: An Undiscovered Gem With High Return Potential. The stock gained 45% in six months but since January 2024, it has crashed 25.89% compared to SPY which gained 4.64% year-to-date (as of 19 April 2024). FAST Graphs More specifically, the stock price g ...

Acquisition Strategy - The company plans to continue acquiring medical higher education institutions and healthtech companies as part of its expansion strategy, which may involve material acquisitions[28]. - The company faces risks in identifying suitable acquisition opportunities and integrating acquired institutions, which could adversely affect its strategic objectives[28]. - The company may face challenges related to regulatory approvals for acquisitions, which could impose conditions or restrictions[28]. - The company’s growth strategy may be materially affected if it cannot obtain adequate financing on favorable terms for acquisitions and expansion plans[31]. - Acquisitions contributed approximately 45.2% of total revenue growth in 2023[162]. - The company has a strong acquisition track record, having increased medical school seats by over 27.4% in 2021 and over 36% in 2020 through various acquisitions[193]. - The company intends to selectively pursue M&A opportunities to enhance its medical education services and product portfolio[193]. Financial Risks and Performance - The concentration of revenues in tuition fees for medical courses and health sciences programs poses a risk, as economic or regulatory factors could decrease demand[21]. - The company may require additional funds to support its expansion strategy, and failure to secure financing could materially affect growth plans[21]. - High inflation and economic uncertainty in Brazil could harm the company's financial condition and market performance[23]. - The company may face significant challenges in raising additional capital due to current macroeconomic trends, including high interest rates and rising inflation[31]. - The company reported payroll administrative expenses of 51.1%, 53.1%, and 53.1% for the years ended December 31, 2023, 2022, and 2021, respectively, indicating a significant portion of costs related to labor unions in the higher education sector[74]. - The company generated R$376.1 million in revenue from residency preparatory courses and continuing medical education in 2023[164]. - The company's revenue for the year ended December 31, 2023, was R$2,875.9 million, representing a CAGR of 29.3% since 2021[164]. - Net income for 2023 was R$405.4 million, reflecting a CAGR of 29.4% since 2021[164]. - Adjusted EBITDA for 2023 totaled R$1,165.7 million, with a CAGR of 24.3% since 2021[164]. Regulatory and Compliance Challenges - The company may face liability for incidents at campuses, which could harm its reputation and financial results[50]. - Non-compliance with MEC regulations could lead to sanctions, including suspension of new student admissions and potential penalties affecting operational capabilities[53]. - The company is subject to regular evaluations by MEC, and lower scores could result in decreased enrollments and perceptions of reduced educational quality[52]. - The company may face challenges in maintaining compliance with evolving regulations, which could impact its ability to operate and affect financial performance[56]. - The company is subject to the LGPD, which imposes penalties for non-compliance, including fines of up to 2% of revenue, capped at R$50,000,000[1]. - The company faces potential increased operational and compliance costs due to the complexity of adapting to the LGPD and other privacy regulations[1]. - The company is at risk of regulatory scrutiny and potential sanctions due to its reliance on third-party collaborators for compliance and regulatory activities[1]. Market and Economic Conditions - The Brazilian government's influence on the economy, including interest rate changes and fiscal policies, could impact the company's operations and share price[23]. - Delays in tuition payments from the FIES program may adversely affect cash flows and overall business performance[22]. - Changes to the FIES program may adversely affect cash flows and the number of students enrolled, impacting revenues[34]. - The Brazilian economy experienced a GDP contraction of 4.1% in 2020, followed by growth of 4.6% in 2021, 3.0% in 2022, and 2.9% in 2023[108]. - Brazilian inflation rates were reported at 10.1%, 5.8%, and 4.6% as of December 31 for the years 2021, 2022, and 2023 respectively[106]. - The SELIC rate was increased from 2.75% in March 2021 to 13.75% by August 2022, before being reduced to 10.75% by April 2024[106]. - Political instability in Brazil, including ongoing investigations into corruption, has negatively impacted investor confidence and market perception[105]. Operational Challenges - The company is experiencing significant expansion-related issues, including cash flow management and corporate culture preservation, which may divert management's attention from other business opportunities[47]. - The ability to attract and retain key personnel is critical for the company's success, with a competitive market for qualified employees posing a risk to operational continuity[48]. - The company faces significant competition in distance learning, which may impact its market share and profitability if it fails to adapt[43]. - The company’s ability to maintain quality standards while expanding new campuses is critical to avoid losing market share[42]. - The company faces challenges in updating and developing educational programs to remain competitive, which may adversely affect student attraction and retention[47]. Student Enrollment and Satisfaction - As of December 31, 2023, Afya Brazil had 66,034 undergraduate students, with 42,563 in health-related fields and 23,471 in non-health-related fields[147]. - The company achieved a Net Promoter Score (NPS) of 40 for medical students graduating less than two years ago, indicating high satisfaction levels[177]. - Increased student attrition rates may negatively impact enrollment numbers and revenue, particularly during economic uncertainty[50]. - The average payback period for medical graduates in Brazil is five years, with nearly 100% employability[216]. Strategic Initiatives and Future Plans - The company aims to maintain its status as a foreign private issuer, which could significantly reduce regulatory and compliance costs compared to U.S. domestic issuers[137]. - The company plans to open seven new medical school campuses under the "Mais Médicos" program, contributing an additional 350 medical school seats per year[150]. - The company aims to expand its network of medical school seats to approximately 3,113 operating seats by the end of 2023, up from 2,773 in 2022[157]. - The company plans to expand its distribution channels by launching graduate courses or CME for third-party continuing medical education hubs[192]. - The company aims to develop new products, including new medical webseries seasons and a virtual reality product, to meet growing student demands[196]. Intellectual Property and Brand Management - The company has 375 trademark registrations in Brazil and 169 pending trademark applications, indicating a focus on protecting intellectual property[57]. - The company has no issued patents as of the report date, which may limit its competitive advantages in the market[57]. - The company is exposed to potential intellectual property claims that could be costly to defend and harm its financial condition if not resolved favorably[60]. - Maintaining brand recognition is critical for the company, as failure to enhance brand awareness could lead to reduced student enrollments and negatively impact financial results[52]. Environmental and Social Governance (ESG) - The company acknowledges climate change as a risk factor that could impact its supply chain and operational stability due to extreme weather events[1]. - The company is committed to reducing its carbon footprint by transitioning to digital educational materials, minimizing physical printing[1]. - Failure to meet ESG commitments could materially impact the company's reputation and financial condition[1]. - The company may face increased compliance costs and regulatory requirements related to environmental matters, which could affect its business opportunities[1].

In the latest market close, Afya (AFYA) reached $18.13, with a -1.47% movement compared to the previous day. This change lagged the S&P 500's daily loss of 1.23%. Elsewhere, the Dow saw a downswing of 1.36%, while the tech-heavy Nasdaq depreciated by 1.4%.The medical education company's shares have seen a decrease of 9.05% over the last month, not keeping up with the Consumer Discretionary sector's loss of 0.81% and the S&P 500's gain of 1.61%.The upcoming earnings release of Afya will be of great interest ...

Pekic Afya (NASDAQ:AFYA) is one of the leading private medical education providers in Brazil. I covered the company in December 2023 with a Hold rating. I liked the company's quality characteristics but believed the price was high. In this review, I analyze the company's 4Q23 and FY24 guidance and its investors' day. My conclusion is that considering FY24 guidance, the company is attractively priced at these levels, balancing present profitability and future growth. That's why I'm upgrading the rating t ...

Financial Data and Key Metrics Changes - Adjusted net revenue for 2023 increased by 24% year-over-year, reaching R$2,874 million, while adjusted EBITDA grew by over 21% to R$1,166 million, with a margin of 40.6% [4][5] - Cash flow from operating activities reached R$1,088.8 million, reflecting a 24% increase compared to the previous year, with a cash conversion rate of 97% [5][17] - Adjusted net income for 2023 was R$591 million, marking an 11% growth year-over-year, with an EPS of R$6.37, a 12% increase compared to the previous year [5][18] Business Line Data and Key Metrics Changes - The number of undergrad medical students grew by 19% year-over-year, reaching over 21,000, with operating seats increasing by over 12% to 3,113 [6][18] - Continuing education segment net revenue expanded by more than 35% year-over-year, reaching R$147 million [6][19] - Digital health services revenue increased by 21% year-over-year, reaching R$229 million, driven by B2B engagements and new contracts [6][20] Market Data and Key Metrics Changes - The ecosystem now has 268,000 active users, representing significant penetration among physicians and medical students in Brazil [7][20] - The average net ticket for medical courses increased by 8.2% year-over-year, reaching R$8,548 [19] Company Strategy and Development Direction - The company aims to maintain strong growth across all segments, with guidance for 2024 indicating net revenue between R$3,150 million and R$3,250 million and adjusted EBITDA between R$1.3 billion and R$1.4 billion [10] - The strategy includes expanding B2B contracts and enhancing digital services, with a focus on operational efficiency and margin expansion across all segments [8][32] Management's Comments on Operating Environment and Future Outlook - Management noted a strong demand for medical education, with a candidate-to-seat ratio of almost six candidates per seat, indicating a competitive environment [25] - The company expects to see margin expansions across all segments in 2024, driven by operational leverage and the full integration of recent acquisitions [30][45] Other Important Information - The company has made significant investments in sustainability, with photovoltaic plants contributing to renewable energy generation and achieving zero greenhouse gas emissions from electricity consumption [11][12] - The workforce is diverse, with 58% female employees and a commitment to increasing female representation in leadership roles [12][13] Q&A Session Summary Question: Competitive environment for 2024 and Mais Médicos auction expectations - Management reported a strong intake process with a candidate-to-seat ratio of almost six, indicating no significant changes in competition compared to last year [25] - The Mais Médicos auction proposals are expected to be delivered by July 2024, with results anticipated in early 2025 [26] Question: Outlook for digital education margins and continuing education expansion - Management expects margin expansions in all segments, with continuing education projected to grow by around 20% in 2024 [30][32] Question: Growth in B2B digital services and M&A activity - B2B contracts grew over 60% year-over-year, with expectations for continued growth driven by new contracts with pharmaceutical companies [36][38] - M&A discussions are ongoing, with a focus on targets that generate significant revenue from medical education [40] Question: Authorization of new seats and impact on competition - Management anticipates potential authorization of 9,000 to 10,000 additional medical seats over the next five to six years, which could impact the competitive landscape [44] Question: Margin expansion responsibility among segments - The undergrad segment is expected to see margin expansion due to the full-year integration of recent acquisitions, while continuing education will benefit from operational leverage [45][46]

NOVA LIMA, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the fourth quarter and full-year period ended December 31, 2023. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2023 Highlights 4Q23 Adjusted Net Revenue increas ...

Afya Limited Consolidated financial statements as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Afya Limited Opinion on the Financial Statements We have audited the accompanying consolidated statements of financial position of Afya Limited (the Company) as of December 31, 2023 and 2022, the related consolidated statements of income and comprehensive income, chang ...

Company Performance - Afya (AFYA) closed at $20.74, reflecting a +1.52% change from the previous session, outperforming the S&P 500's daily gain of 1.12% [1] - Over the past month, Afya's shares have decreased by 2.81%, while the Consumer Discretionary sector and S&P 500 gained 1.03% and 2.06%, respectively [1] - Afya is projected to report earnings of $0.34 per share, indicating a year-over-year growth of 30.77%, with revenue estimates at $141.83 million, representing a 27.8% increase compared to the same quarter last year [1] Analyst Forecasts - Recent revisions to analyst forecasts for Afya are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [2] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Afya at 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [2] Valuation Metrics - Afya is trading at a Forward P/E ratio of 13.32, which is below the industry average Forward P/E of 18.35 [3] - The company has a PEG ratio of 0.76, compared to the Schools industry's average PEG ratio of 1.16 [3] - The Schools industry, part of the Consumer Discretionary sector, holds a Zacks Industry Rank of 22, placing it in the top 9% of over 250 industries [3]